Earnings call transcript: PDS Biotech’s Q4 2025 results show improved financial discipline

TL;DR

Earnings call transcript: ACG’s Q4 2025 shows revenue decline, market steady Earnings call transcript: Soul Patts reports strong H1 2026 results Earnings call transcript: Methanex Q4 2025 misses expectations, stock dips Earnings call transcript: Fleury SA Q4 2025 sees mixed market reaction Earnings call transcript: StandardAero Q4 2025 reports record revenue growth Earnings call transcript: Compass Q4 2025 sees record revenue, stock up 2.5% Earnings call transcript: Cryoport Q4 2025 misses EPS, stock rises on revenue beat Earnings call transcript: California Resources Q4 2025 results reveal revenue surprise, EPS miss Earnings call transcript: Syndax Pharmaceuticals Q4 2025 revenue beats forecast, stock rises Earnings call transcript: Inovio Q4 2025 earnings miss, stock dips Earnings call transcript: FIGR misses Q4 2025 EPS forecast, stock drops 27% H&M Earnings Rise as Cost Control Offsets Subdued Sales Earnings call transcript: DEME’s Q4 2025 earnings surpass expectations Earnings call transcript: Evolv Technologies Q4 2025 reports revenue growth Earnings call transcript: THG Holdings sees stock rise after H2 2025 recovery Earnings call transcript: Capricorn Energy’s H2 2025 transformation bolsters near debt-free status Earnings call transcript: Bathurst Resources misses Q1 2026 EPS, stock rises 7.2% Earnings call transcript: Racing Force Group reports strong H2 2025 growth Earnings call transcript: Enerpac Tool Group’s Q2 2026 results show mixed signals Earnings call transcript: X Financial’s Q4 2025 results show sharp profitability decline Earnings call transcript: Hyperion DeFi Q4 2025 shows robust growth Earnings call transcript: Lumexa Imaging Q4 2025 reveals unexpected EPS miss Earnings call transcript: Ser Educacional Q4 2025 sees stock surge on strong results Earnings call transcript: KNOP Q4 2025 results show mixed signals Earnings call transcript: BRP Inc. surpasses Q4 2026 expectations with robust growth Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management Earnings call transcript: Shoe Carnival Q4 2025 beats EPS forecasts, shares fall Earnings call transcript: The Dixie Group sees improved margins in Q4 2025 Earnings call transcript: Stran & Co Q4 2025 shows strong revenue growth Earnings call transcript: Anaergia Inc. Q4 2025 shows strong revenue growth Key Points - BRP finished fiscal 2026 above guidance with CAD 8.4 billion in revenue, CAD 1.1 billion normalized EBITDA, normalized EPS of CAD 5.21 and free cash flow > CAD 900 million, ending the year with > CAD 400 million in cash, net leverage 1.8x, a 16% dividend increase and continued share‑buyback activity.